-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Previous studies have confirmed that PD-1 inhibitors combined with chemotherapy are effective as first-line treatment for metastatic non-small cell lung cancer (NSCLC)
.
However, there is currently no evidence that PD-L1 inhibitors combined with chemotherapy have a therapeutic effect in patients with squamous and non-squamous NSCLC
.
There is currently no evidence that PD-L1 inhibitors combined with chemotherapy have a therapeutic effect in patients with squamous and non-squamous NSCLC
GEMSTONE-302 is a randomized, double-blind Phase 3 clinical trial conducted in 35 hospitals and academic research centers in China to evaluate the efficacy of PD-L1 inhibitor sugemalimab in combination with chemotherapy in patients with metastatic squamous cell carcinoma.
Efficacy and safety in patients with squamous or non-squamous NSCLC
To evaluate the efficacy and safety of the PD-L1 inhibitor sugemalimab in combination with chemotherapy in patients with metastatic squamous or non-squamous NSCLC
median progression-free survival
median progression-free survivalBetween December 13, 2018, and May 15, 2020, a total of 846 patients were evaluated, of whom 479 were randomized to sugelimumab (n=320) or placebo (n=159)
.
With a median follow-up of 8.
6 months as of June 8, 2020 (interim analysis), median progression-free survival was significantly longer in the sugelimumab group compared with the placebo group (7.
Median progression-free survival was significantly longer in the sugalimumab group compared to placebo The median progression-free survival was 9.
overall survival
overall survivalThe most common grade 3-4 treatment-related adverse events were decreased neutrophil count (sugalimab vs placebo: 33% vs 33%), decreased white blood cell count (14% vs 17%), anemia (13% vs 11%), decreased platelet count (10% vs 9%), and neutropenia (4% vs 4%)
.
Treatment-related serious adverse events were experienced by 73 (23%) and 31 (20%) patients in the sugelimab group and placebo group, respectively
.
some side reactions
some side reactionsIn conclusion, compared with placebo plus chemotherapy, sugalimab plus chemotherapy significantly prolonged progression-free survival in patients with previously untreated squamous and non-squamous metastatic NSCLC, or in patients with metastatic non-small cell lung cancer New first-line treatment options for patients
Compared with placebo combined with chemotherapy, sugalimab combined with chemotherapy significantly prolongs progression-free survival in patients with previously untreated squamous and non-squamous metastatic NSCLC Choice of first-line treatment regimen compared with placebo plus chemotherapy, sugalimab plus chemotherapy significantly prolongs progression-free survival in patients with previously untreated squamous and non-squamous metastatic NSCLC, or may become a New first-line treatment options for patients with small cell lung cancer
Original source:
Original source:Caicun Zhou, et al.
leave a message here
